Venture Model Makeover & Diet Plan—Step One

A lot of people have been asking lately if the venture model is broken. But it seems to me that it’s just decrepit. Like an aging, rotund former football star, the venture industry is scratching its head and realizing that its glory days are long past. The industry collectively doesn’t really know how to handle its new reality. In the heyday, top-quartile funds might have gotten away with treating their important stakeholders arrogantly, but given that even top-quartile firms have not provided great returns over the past 10 years, venture GPs will need to make herculean efforts and adhere to a strict regimen in order to make the upcoming cut. With almost the entire industry needing to raise new funds over the next two years, there may be few survivors. I propose a three-step makeover plan for those paunchy firms that are on the edge.

Step one: Stop devouring entrepreneurs. These tasty morsels can be irresistible, to be sure. They work for years to create a business, innovate, and execute, and they bring the fruits of their labors to you. GPs, you must learn to control your appetite and realize that these individuals are not going to continue to feed you if you chew them up and spit them out.

A case in point was hinted at in an earlier post about “down” being “the new up” by Michael Greeley of Flybridge Capital Partners, chairman of the New England Venture Capital Association and a board member of the National Venture Capital Association. Greeley made the argument that venture-backed companies “should be considered fortunate to just raise capital, at any price, in this environment.” I don’t mean to pick on Michael, as he is only reporting on the current prevalence of this kind of thinking among VCs, but why should a company be lucky to take in financing that wipes out the ownership of everyone but the venture funds who participate, just because we are now in a tough economy? Venture capital is a long-term game that is meant to take companies to an exit years from now when the economy will probably be completely different.

One could argue that it’s only reasonable and good business to protect the venture firm’s downside at the founding team’s expense, but is that really true? Usually the founders are only left with a small percentage of the company after a few rounds of funding even in the best-case scenarios, so for an additional 5 to 15 percent of the equity is it really worth

Author: Daphne Zohar

Daphne Zohar is the co-founder and CEO of PureTech, a Boston-based firm specializing in translating breakthrough research from top tier academic institutions into therapies that will impact human health and well-being. PureTech’s senior partners include entrepreneurs and leaders from the highest echelon of pharma, biotech and academia. Ms. Zohar was named one of the world's top young innovators who will shape the future of technology by MIT's Technology Review magazine and one of the top "40 under 40" by the Boston Business Journal. A successful entrepreneur, Zohar created PureTech and assembled a leading team to help implement her vision for the firm. She co-founded and sits on the Boards of Directors of PureTech, Solace Pharmaceuticals (where she was founding CEO), Follica Inc. (where she was founding CEO), Enlight Biosciences (a technology development company whose backers include Merck, Pfizer, Lilly, Johnson & Johnson, and Novartis), Endra, and Satori Pharmaceuticals (where she was founding CEO). She also sits on the Technology Development Fund Advisory Board at Children's Hospital Boston, the Tufts University School of Medicine Advisory Committee for Drug Discovery and Development, and is an editorial advisor to Xconomy, a national technology news blog.